Priapism Linked to Antipsychotic-Gabapentinoid Use

Priapism, a prolonged and often painful penile erection unassociated with sexual arousal, stands as a rare but critical urological emergency. Medical professionals recognize it as a condition that demands urgent intervention to preclude serious long-term sequelae such as fibrosis and erectile dysfunction. The pathophysiology of priapism commonly involves dysregulation of vascular tone and smooth muscle activity within the corpora cavernosa, leading to impaired venous outflow and persistent erection. Notably, drug-induced priapism constitutes a significant subset of cases, with several pharmacological classes implicated—among them antipsychotics, antidepressants, anticonvulsants, and antihypertensives.

In an eye-opening case report recently published in BMC Psychiatry, researchers Haque, Shastri, Naguib, and colleagues detailed an incident of ischaemic priapism precipitated by the concomitant use of antipsychotic medication and a gabapentinoid in a patient diagnosed with treatment-resistant schizophrenia. The subject, a 36-year-old male with a compendium of chronic substance use including crack cocaine, heroin, methamphetamine, and pregabalin, developed this urologic emergency during an exacerbation of psychosis under psychiatric intensive care. This case underscores the intricate interplay between psychiatric medications and their vascular side effects, inviting deeper clinical vigilance.

The medication regimen of the patient at the time included a well-established long-term administration of zuclopenthixol decanoate, a first-generation antipsychotic administered intramuscularly at a dose of 500 mg weekly. Recently, low-dose pregabalin had been introduced (75 mg twice daily) to manage pre-existing neuropathic pain symptoms. Pregabalin, a gabapentinoid, is acknowledged for its utility in neuropathic pain syndromes but is less extensively studied in its interactions with antipsychotic agents. The Naranjo adverse reaction probability scale—a validated tool to determine the likelihood of drug-induced adverse effects—was employed, yielding a score of seven. This numeric value supports a probable causal link between the combined pharmacotherapy and the onset of ischaemic priapism.

Ischaemic priapism is characterized by the cessation of arterial inflow and stagnation of deoxygenated blood, resulting in hypoxia and acidosis within the penile tissue. This pathophysiological state differentiates it decisively from non-ischaemic (high-flow) priapism, which generally carries a less emergent prognosis. Prompt diagnosis, often informed by clinical presentation and confirmed via penile blood gas analysis or Doppler ultrasonography, dictates therapeutic intervention to restore normal hemodynamics and prevent irreversible damage.

The underlying mechanisms by which the gabapentinoid–antipsychotic combination culminates in priapism remain incompletely elucidated. However, prevailing theories suggest that antagonism or modulation of alpha-adrenergic receptors by antipsychotics, compounded by gabapentinoids’ influence on calcium channel subunits, may disrupt vascular smooth muscle tone. These pharmacodynamic actions could impair the delicate balance necessary for normal penile detumescence. Moreover, pregabalin’s modulation of neurotransmitter release could exacerbate vascular dysregulation in the context of chronic antipsychotic exposure.

This case has critical implications for psychiatric practice, especially given the increasing off-label use of gabapentinoids in mental health settings for pain management and anxiety disorders. The risk of priapism, though rare, mandates heightened clinical awareness when initiating or adjusting gabapentinoid therapy in patients already maintained on long-acting antipsychotics. Delayed recognition and treatment of priapism can lead to serious morbidity including permanent erectile dysfunction, thereby profoundly affecting quality of life.

The report also highlights the challenges encountered in psychiatric inpatient environments where complex polypharmacy and comorbid substance misuse may obscure symptomatology and delay emergent diagnosis. Substance abuse, as in this patient, may sensitize vascular responses or further convolute pharmacokinetic profiles, complicating clinical management. Consequently, multidisciplinary strategies integrating psychiatry, urology, and pharmacology expertise are paramount for optimizing patient outcomes.

A takeaway from this case emphasizes the necessity for structured monitoring protocols tailored for patients receiving antipsychotic-gabapentinoid combinations. Guidelines should prioritize patient education on early symptoms of priapism and clear pathways for urgent medical evaluation. Moreover, the integration of risk stratification tools could aid in identifying susceptible individuals, thus preemptively guiding therapeutic decisions.

Ultimately, this case report serves as a sentinel warning about the vascular side effect risks entrenched in psychiatric pharmacotherapy. It catalyzes calls for further rigorous research into the mechanistic interactions between novel combination therapies and vascular physiology. Such investigations are vital to refine safe prescribing practices, especially as the pharmacological landscape in psychiatry becomes increasingly complex and personalized.

In conclusion, ischaemic priapism following the combination of antipsychotics and gabapentinoids in treatment-resistant schizophrenia is a serious adverse effect that demands immediate clinical attention. This unique case not only sheds light on an underappreciated pharmacological hazard but also reinforces the imperative for cautious prescribing and vigilant monitoring within psychiatric settings. As the use of gabapentinoids grows alongside antipsychotics, embracing a proactive stance toward identifying and managing rare but formidable complications like priapism will become increasingly critical.